Albeit without significance, serum CXCL10 levels were numerically higher at baseline and at the start of the second course and more strongly increased from baseline to the start of the second course among responders than among non‐responders in the initial therapeutic response assessment of patients with BCLC stage C HCC (Figure 1). Here, CXCL10 is linked to hepatocellular carcinoma.